Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Annovis Bio Inc (NY: ANVS )

7.650 -0.380 (-4.73%)
Streaming Delayed Price Updated: 10:15 AM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Annovis Bio Inc

< Previous 1 2 3 4 5 Next >
Annovis Bio Stock Crashes After Much-Hyped Alzheimer's Drug Flops In Midstage Test
Annovis Bio's Alzheimer's drug failed to significantly outperform the placebo in a midstage test, leading ANVS stock to plummet on Thursday. 
Via Investor's Business Daily
28 Stocks Moving in Thursday's Pre-Market Session
Gainers LendingClub Corporation (NYSE: LC) shares rose 44.6% to $23.49 in pre-market trading after the company reported better-than-expected Q2 results and raised guidance. Acer... 
Via Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Exposures COVID-19
Why Annovis Stock Is Bucking The Trend In Alzheimer's — And Two Others To Watch
Annovis bucked the trend depressing Alzheimer's stocks on Friday as ANVS stock touched a record high while SAVA stock and INMB stock fell. 
Via Investor's Business Daily
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
Annovis Bio's Alzheimer's Candidate To Proceed Into Final Cohort Of Mid-Stage Study, Data Expected In 2022
Data Safety Monitoring Board (DSMB) has reviewed safety and tolerability data for Cohort 2 of Annovis Bio Inc's (NYSE: ANVS) Phase 2 Alzheimer's disease trial... 
Via Benzinga
Got $2,500? Check Out These 3 Alzheimer's Therapy Stocks
Treating Alzheimer's is extremely difficult, but these innovative companies are taking a stab at it. 
Via The Motley Fool
Here's Why The Biotech Stocks You Bought Keep Going Down
Good news! There's a way to avoid this portfolio pain -- and it doesn't involve avoiding the whole sector. 
Via The Motley Fool
Better Biotech Stock: Biogen vs. Annovis Bio
Both are making Alzheimer's drugs, but only one can claim success as of today. 
Via The Motley Fool
38 Stocks Moving In Monday's Mid-Day Session
Gainers State Auto Financial Corporation (NASDAQ: STFC) shares jumped 189.5% to $49.96 after the company agreed to be acquired by Liberty Mutual Insurance for $52 per share in... 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers MediaCo Holding Inc. (NASDAQ: MDIA) shares jumped 311.6% to close at $17.00 on Monday after jumping 20% on Friday. State Auto Financial Corporation (NASDAQ: STFC) shares... 
Via Benzinga
Neurodegenerative Disease And Cancer Stocks Among Top Biotech Gainers In 2021
Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF IBB advancing about 8% year-to-date compared to the roughly 14% gain for the S&P... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021
Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) advancing about 8% year-to-date ... 
Via Benzinga
44 Biggest Movers From Yesterday
Gainers Alfi, Inc. (NASDAQ: ALF) shares jumped 108.9% to settle at $16.29 on Tuesday following exclusive Benzinga reporting the company will buyback up to $2 million of its... 
Via Benzinga
These 2 Biotech Stocks Are Up 1,000% This Year
New approaches to treating Alzheimer's could mean even bigger gains in the future. 
Via The Motley Fool
Stocks That Hit 52-Week Highs On Thursday
This morning 94 companies set new 52-week highs. Things to Consider: NVIDIA (NASDAQ:NVDA) was the largest firm by market cap to set a new 52-week high. Deswell Industries... 
Via Benzinga
64 Biggest Movers From Friday
Gainers Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per share. Novan, Inc. (NASDAQ: NOVN) shares gained... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Biotechs Ready To Roar
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... 
Via Talk Markets
Exposures Product Safety
46 Stocks Moving In Friday's Mid-Day Session
Gainers Kanzhun Limited (NASDAQ: BZ) shares surged 77.4% to $33.70 after the company priced its IPO at $19 per share. Novan, Inc. (NASDAQ: NOVN) shares jumped 73.3% to $15.67... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Ignore Biogen: 3 Reasons These Stocks Will Be Better Alzheimer's Investments
Data doesn't lie. These companies have the potential to quickly steal the spotlight. 
Via The Motley Fool
Exposures Product Safety
This Biotech Stock Is Up 884% In 2021, But It Could Go Even Higher
With updates from clinical trials expected as soon as this month, anything is possible. 
Via The Motley Fool
Biogen Snagged: Will Hefty Price Tag Hinder Alzheimer's Drug Use?
Biogen stock dipped Tuesday as analysts questioned how much use its potential blockbuster Alzheimer's treatment, Aduhelm, would ultimately secure. 
Via Investor's Business Daily
Annovis' Alzheimer's/Parkinson's Candidate Protects Nerve Cells Against Ill Effects of Higher Neurotoxic Proteins
Annovis Bio Inc (NYSE: ANVS) has announced preliminary data demonstrating that ANVS401 protects certain nerve cells from dying after being infected by gingipains, which... 
Via Benzinga
Forget Biogen: These 2 Alzheimer's Drug Stocks Could Make You Rich
There are better options for investors looking to profit from potential Alzheimer's disease treatments. 
Via The Motley Fool
Exposures Product Safety
Biogen Wins Landmark Alzheimer's Approval: 5 Things To Know About Aducanumab
The FDA approved Biogen's Alzheimer's treatment, aducanumab, on Monday — though Biogen stock remained halted into the long-awaited decision. 
Via Investor's Business Daily
Exposures Product Safety
68 Biggest Movers From Yesterday
Gainers Orbital Energy Group, Inc. (NASDAQ: OEG) shares surged 115.2% to close at $7.64 on Tuesday after the company announced its subsidiary, Gibson Technical Services, reached... 
Via Benzinga
22 Stocks Moving in Monday's Pre-Market Session
Gainers Virgin Galactic Holdings, Inc. (NYSE: SPCE) rose 29.3% to $27.25 in pre-market trading. Virgin Galactic’s VSS Unity spacecraft completed its first spaceflight from... 
Via Benzinga
54 Biggest Movers From Yesterday
Gainers Flanigan's Enterprises, Inc. (NYSE: BDL) shares surged 40.6% to close at $34.90 on Tuesday after the company reported results for the 13 weeks and the 26 weeks ended... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street; Crude Oil Rises
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones surged over 100 points in the previous session. Investors are awaiting earnings... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
48 Biggest Movers From Friday
Gainers Annovis Bio, Inc. (NASDAQ: ANVS) shares surged 127.3% to close at $60.00 on Friday after the company announced new results from a Phase 2 study evaluating its lead drug... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.